|
Fusion Gene Summary | |
Fusion Gene ORF analysis | |
Fusion Genomic Features | |
Fusion Protein Features | |
Fusion Gene Sequence | |
Fusion Gene PPI analysis | |
Related Drugs | |
Related Diseases |
Fusion gene:PDE4D-NLK (FusionGDB2 ID:63330) |
Fusion Gene Summary for PDE4D-NLK |
Fusion gene summary |
Fusion gene information | Fusion gene name: PDE4D-NLK | Fusion gene ID: 63330 | Hgene | Tgene | Gene symbol | PDE4D | NLK | Gene ID | 5144 | 51701 |
Gene name | phosphodiesterase 4D | nemo like kinase | |
Synonyms | ACRDYS2|DPDE3|HSPDE4D|PDE43|PDE4DN2|STRK1 | - | |
Cytomap | 5q11.2-q12.1 | 17q11.2 | |
Type of gene | protein-coding | protein-coding | |
Description | cAMP-specific 3',5'-cyclic phosphodiesterase 4DcAMP-specific phosphodiesterase PDE4D6phosphodiesterase 4D, cAMP-specific (phosphodiesterase E3 dunce homolog, Drosophila)testicular tissue protein Li 136 | serine/threonine-protein kinase NLK | |
Modification date | 20200313 | 20200313 | |
UniProtAcc | . | Q9UBE8 | |
Ensembl transtripts involved in fusion gene | ENST00000340635, ENST00000360047, ENST00000507116, ENST00000502484, ENST00000546160, ENST00000502575, ENST00000358923, ENST00000503258, ENST00000405755, ENST00000317118, ENST00000503947, | ENST00000407008, ENST00000583517, ENST00000582037, | |
Fusion gene scores | * DoF score | 40 X 32 X 12=15360 | 10 X 10 X 5=500 |
# samples | 56 | 15 | |
** MAII score | log2(56/15360*10)=-4.77760757866355 possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs). DoF>8 and MAII<0 | log2(15/500*10)=-1.73696559416621 possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs). DoF>8 and MAII<0 | |
Context | PubMed: PDE4D [Title/Abstract] AND NLK [Title/Abstract] AND fusion [Title/Abstract] | ||
Most frequent breakpoint | PDE4D(59284315)-NLK(26449629), # samples:1 | ||
Anticipated loss of major functional domain due to fusion event. | PDE4D-NLK seems lost the major protein functional domain in Hgene partner, which is a cell metabolism gene due to the frame-shifted ORF. PDE4D-NLK seems lost the major protein functional domain in Hgene partner, which is a IUPHAR drug target due to the frame-shifted ORF. PDE4D-NLK seems lost the major protein functional domain in Tgene partner, which is a kinase due to the frame-shifted ORF. PDE4D-NLK seems lost the major protein functional domain in Tgene partner, which is a IUPHAR drug target due to the frame-shifted ORF. |
* DoF score (Degree of Frequency) = # partners X # break points X # cancer types ** MAII score (Major Active Isofusion Index) = log2(# samples/DoF score*10) |
Gene ontology of each fusion partner gene with evidence of Inferred from Direct Assay (IDA) from Entrez |
Partner | Gene | GO ID | GO term | PubMed ID |
Tgene | NLK | GO:0050821 | protein stabilization | 25512613 |
Fusion gene breakpoints across PDE4D (5'-gene) * Click on the image to open the UCSC genome browser with custom track showing this image in a new window. |
Fusion gene breakpoints across NLK (3'-gene) * Click on the image to open the UCSC genome browser with custom track showing this image in a new window. |
Fusion gene information from two resources (ChiTars 5.0 and ChimerDB 4.0) * All genome coordinats were lifted-over on hg19. * Click on the break point to see the gene structure around the break point region using the UCSC Genome Browser. |
Source | Disease | Sample | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand |
ChimerDB4 | PRAD | TCGA-G9-6499 | PDE4D | chr5 | 59284315 | - | NLK | chr17 | 26449629 | + |
Top |
Fusion Gene ORF analysis for PDE4D-NLK |
Open reading frame (ORF) analsis of fusion genes based on Ensembl gene isoform structure. * Click on the break point to see the gene structure around the break point region using the UCSC Genome Browser. |
ORF | Henst | Tenst | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand |
intron-3CDS | ENST00000340635 | ENST00000407008 | PDE4D | chr5 | 59284315 | - | NLK | chr17 | 26449629 | + |
intron-intron | ENST00000340635 | ENST00000583517 | PDE4D | chr5 | 59284315 | - | NLK | chr17 | 26449629 | + |
intron-intron | ENST00000340635 | ENST00000582037 | PDE4D | chr5 | 59284315 | - | NLK | chr17 | 26449629 | + |
intron-3CDS | ENST00000360047 | ENST00000407008 | PDE4D | chr5 | 59284315 | - | NLK | chr17 | 26449629 | + |
intron-intron | ENST00000360047 | ENST00000583517 | PDE4D | chr5 | 59284315 | - | NLK | chr17 | 26449629 | + |
intron-intron | ENST00000360047 | ENST00000582037 | PDE4D | chr5 | 59284315 | - | NLK | chr17 | 26449629 | + |
intron-3CDS | ENST00000507116 | ENST00000407008 | PDE4D | chr5 | 59284315 | - | NLK | chr17 | 26449629 | + |
intron-intron | ENST00000507116 | ENST00000583517 | PDE4D | chr5 | 59284315 | - | NLK | chr17 | 26449629 | + |
intron-intron | ENST00000507116 | ENST00000582037 | PDE4D | chr5 | 59284315 | - | NLK | chr17 | 26449629 | + |
Frame-shift | ENST00000502484 | ENST00000407008 | PDE4D | chr5 | 59284315 | - | NLK | chr17 | 26449629 | + |
5CDS-intron | ENST00000502484 | ENST00000583517 | PDE4D | chr5 | 59284315 | - | NLK | chr17 | 26449629 | + |
5CDS-intron | ENST00000502484 | ENST00000582037 | PDE4D | chr5 | 59284315 | - | NLK | chr17 | 26449629 | + |
In-frame | ENST00000546160 | ENST00000407008 | PDE4D | chr5 | 59284315 | - | NLK | chr17 | 26449629 | + |
5CDS-intron | ENST00000546160 | ENST00000583517 | PDE4D | chr5 | 59284315 | - | NLK | chr17 | 26449629 | + |
5CDS-intron | ENST00000546160 | ENST00000582037 | PDE4D | chr5 | 59284315 | - | NLK | chr17 | 26449629 | + |
intron-3CDS | ENST00000502575 | ENST00000407008 | PDE4D | chr5 | 59284315 | - | NLK | chr17 | 26449629 | + |
intron-intron | ENST00000502575 | ENST00000583517 | PDE4D | chr5 | 59284315 | - | NLK | chr17 | 26449629 | + |
intron-intron | ENST00000502575 | ENST00000582037 | PDE4D | chr5 | 59284315 | - | NLK | chr17 | 26449629 | + |
intron-3CDS | ENST00000358923 | ENST00000407008 | PDE4D | chr5 | 59284315 | - | NLK | chr17 | 26449629 | + |
intron-intron | ENST00000358923 | ENST00000583517 | PDE4D | chr5 | 59284315 | - | NLK | chr17 | 26449629 | + |
intron-intron | ENST00000358923 | ENST00000582037 | PDE4D | chr5 | 59284315 | - | NLK | chr17 | 26449629 | + |
intron-3CDS | ENST00000503258 | ENST00000407008 | PDE4D | chr5 | 59284315 | - | NLK | chr17 | 26449629 | + |
intron-intron | ENST00000503258 | ENST00000583517 | PDE4D | chr5 | 59284315 | - | NLK | chr17 | 26449629 | + |
intron-intron | ENST00000503258 | ENST00000582037 | PDE4D | chr5 | 59284315 | - | NLK | chr17 | 26449629 | + |
intron-3CDS | ENST00000405755 | ENST00000407008 | PDE4D | chr5 | 59284315 | - | NLK | chr17 | 26449629 | + |
intron-intron | ENST00000405755 | ENST00000583517 | PDE4D | chr5 | 59284315 | - | NLK | chr17 | 26449629 | + |
intron-intron | ENST00000405755 | ENST00000582037 | PDE4D | chr5 | 59284315 | - | NLK | chr17 | 26449629 | + |
intron-3CDS | ENST00000317118 | ENST00000407008 | PDE4D | chr5 | 59284315 | - | NLK | chr17 | 26449629 | + |
intron-intron | ENST00000317118 | ENST00000583517 | PDE4D | chr5 | 59284315 | - | NLK | chr17 | 26449629 | + |
intron-intron | ENST00000317118 | ENST00000582037 | PDE4D | chr5 | 59284315 | - | NLK | chr17 | 26449629 | + |
intron-3CDS | ENST00000503947 | ENST00000407008 | PDE4D | chr5 | 59284315 | - | NLK | chr17 | 26449629 | + |
intron-intron | ENST00000503947 | ENST00000583517 | PDE4D | chr5 | 59284315 | - | NLK | chr17 | 26449629 | + |
intron-intron | ENST00000503947 | ENST00000582037 | PDE4D | chr5 | 59284315 | - | NLK | chr17 | 26449629 | + |
ORFfinder result based on the fusion transcript sequence of in-frame fusion genes. |
Henst | Tenst | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand | Seq length (transcript) | BP loci (transcript) | Predicted start (transcript) | Predicted stop (transcript) | Seq length (amino acids) |
ENST00000546160 | PDE4D | chr5 | 59284315 | - | ENST00000407008 | NLK | chr17 | 26449629 | + | 3143 | 272 | 0 | 1397 | 465 |
DeepORF prediction of the coding potential based on the fusion transcript sequence of in-frame fusion genes. DeepORF is a coding potential classifier based on convolutional neural network by comparing the real Ribo-seq data. If the no-coding score < 0.5 and coding score > 0.5, then the in-frame fusion transcript is predicted as being likely translated. |
Henst | Tenst | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand | No-coding score | Coding score |
ENST00000546160 | ENST00000407008 | PDE4D | chr5 | 59284315 | - | NLK | chr17 | 26449629 | + | 0.000355982 | 0.99964404 |
Top |
Fusion Genomic Features for PDE4D-NLK |
FusionAI prediction of the potential fusion gene breakpoint based on the pre-mature RNA sequence context (+/- 5kb of individual partner genes, total 20kb length sequence). FusionAI is a fusion gene breakpoint classifier based on convolutional neural network by comparing the fusion positive and negative sequence context of ~ 20K fusion gene data. From here, we can have the relative potentency of the 20K genomic sequence how individual sequnce will be likely used as the gene fusion breakpoints. |
Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand | 1-p | p (fusion gene breakpoint) |
PDE4D | chr5 | 59284314 | - | NLK | chr17 | 26449628 | + | 2.35E-07 | 0.99999976 |
PDE4D | chr5 | 59284314 | - | NLK | chr17 | 26449628 | + | 2.35E-07 | 0.99999976 |
Distribution of 44 human genomic features loci across 20kb length fusion breakpoint regions. We integrated a total of 44 different types of human genomic feature loci information across five big categories including virus integration sites, repeats, structural variants, chromatin states, and gene expression regulation. More details are in help page. |
Distribution of 44 human genomic features loci across 20kb length fusion breakpoint regions that are ovelapped with the top 1% feature importance score regions. More details are in help page. |
Top |
Fusion Protein Features for PDE4D-NLK |
Go to FGviewer for the breakpoints of chr5:59284315-chr17:26449629 - FGviewer provides the online visualization of the retention search of the protein functional features across DNA, RNA, protein, and pathological levels. |
Main function of each fusion partner protein. (from UniProt) |
Hgene | Tgene |
. | NLK |
FUNCTION: Might normally function as a transcriptional repressor. EWS-fusion-proteins (EFPS) may play a role in the tumorigenic process. They may disturb gene expression by mimicking, or interfering with the normal function of CTD-POLII within the transcription initiation complex. They may also contribute to an aberrant activation of the fusion protein target genes. | FUNCTION: Serine/threonine-protein kinase that regulates a number of transcription factors with key roles in cell fate determination. Positive effector of the non-canonical Wnt signaling pathway, acting downstream of WNT5A, MAP3K7/TAK1 and HIPK2. Negative regulator of the canonical Wnt/beta-catenin signaling pathway. Binds to and phosphorylates TCF7L2/TCF4 and LEF1, promoting the dissociation of the TCF7L2/LEF1/beta-catenin complex from DNA, as well as the ubiquitination and subsequent proteolysis of LEF1. Together these effects inhibit the transcriptional activation of canonical Wnt/beta-catenin target genes. Negative regulator of the Notch signaling pathway. Binds to and phosphorylates NOTCH1, thereby preventing the formation of a transcriptionally active ternary complex of NOTCH1, RBPJ/RBPSUH and MAML1. Negative regulator of the MYB family of transcription factors. Phosphorylation of MYB leads to its subsequent proteolysis while phosphorylation of MYBL1 and MYBL2 inhibits their interaction with the coactivator CREBBP. Other transcription factors may also be inhibited by direct phosphorylation of CREBBP itself. Acts downstream of IL6 and MAP3K7/TAK1 to phosphorylate STAT3, which is in turn required for activation of NLK by MAP3K7/TAK1. Upon IL1B stimulus, cooperates with ATF5 to activate the transactivation activity of C/EBP subfamily members. Phosphorylates ATF5 but also stabilizes ATF5 protein levels in a kinase-independent manner (PubMed:25512613). {ECO:0000250|UniProtKB:O54949, ECO:0000269|PubMed:12482967, ECO:0000269|PubMed:14960582, ECO:0000269|PubMed:15004007, ECO:0000269|PubMed:15764709, ECO:0000269|PubMed:20061393, ECO:0000269|PubMed:20118921, ECO:0000269|PubMed:20874444, ECO:0000269|PubMed:21454679, ECO:0000269|PubMed:25512613}. |
Retention analysis result of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features. Here, because of limited space for viewing, we only show the protein feature retention information belong to the 13 regional features. All retention annotation result can be downloaded at * Minus value of BPloci means that the break pointn is located before the CDS. |
- In-frame and retained protein feature among the 13 regional features. |
Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Protein feature | Protein feature note |
Hgene | PDE4D | chr5:59284315 | chr17:26449629 | ENST00000502484 | - | 3 | 17 | 42_88 | 90.66666666666667 | 749.0 | Compositional bias | Note=Pro-rich |
Hgene | PDE4D | chr5:59284315 | chr17:26449629 | ENST00000546160 | - | 2 | 16 | 42_88 | 90.66666666666667 | 749.0 | Compositional bias | Note=Pro-rich |
Tgene | NLK | chr5:59284315 | chr17:26449629 | ENST00000407008 | 0 | 11 | 298_300 | 152.66666666666666 | 528.0 | Motif | Note=TQE | |
Tgene | NLK | chr5:59284315 | chr17:26449629 | ENST00000407008 | 0 | 11 | 428_527 | 152.66666666666666 | 528.0 | Region | Required for homodimerization and kinase activation and localization to the nucleus |
- In-frame and not-retained protein feature among the 13 regional features. |
Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Protein feature | Protein feature note |
Hgene | PDE4D | chr5:59284315 | chr17:26449629 | ENST00000317118 | - | 1 | 10 | 42_88 | 0 | 519.0 | Compositional bias | Note=Pro-rich |
Hgene | PDE4D | chr5:59284315 | chr17:26449629 | ENST00000340635 | - | 1 | 15 | 42_88 | 0 | 810.0 | Compositional bias | Note=Pro-rich |
Hgene | PDE4D | chr5:59284315 | chr17:26449629 | ENST00000358923 | - | 1 | 11 | 42_88 | 0 | 508.0 | Compositional bias | Note=Pro-rich |
Hgene | PDE4D | chr5:59284315 | chr17:26449629 | ENST00000360047 | - | 1 | 15 | 42_88 | 0 | 674.0 | Compositional bias | Note=Pro-rich |
Hgene | PDE4D | chr5:59284315 | chr17:26449629 | ENST00000405755 | - | 1 | 15 | 42_88 | 0 | 688.0 | Compositional bias | Note=Pro-rich |
Hgene | PDE4D | chr5:59284315 | chr17:26449629 | ENST00000502575 | - | 1 | 6 | 42_88 | 0 | 220.0 | Compositional bias | Note=Pro-rich |
Hgene | PDE4D | chr5:59284315 | chr17:26449629 | ENST00000503258 | - | 1 | 15 | 42_88 | 0 | 680.0 | Compositional bias | Note=Pro-rich |
Hgene | PDE4D | chr5:59284315 | chr17:26449629 | ENST00000507116 | - | 1 | 15 | 42_88 | 0 | 746.0 | Compositional bias | Note=Pro-rich |
Hgene | PDE4D | chr5:59284315 | chr17:26449629 | ENST00000317118 | - | 1 | 10 | 386_715 | 0 | 519.0 | Domain | PDEase |
Hgene | PDE4D | chr5:59284315 | chr17:26449629 | ENST00000340635 | - | 1 | 15 | 386_715 | 0 | 810.0 | Domain | PDEase |
Hgene | PDE4D | chr5:59284315 | chr17:26449629 | ENST00000358923 | - | 1 | 11 | 386_715 | 0 | 508.0 | Domain | PDEase |
Hgene | PDE4D | chr5:59284315 | chr17:26449629 | ENST00000360047 | - | 1 | 15 | 386_715 | 0 | 674.0 | Domain | PDEase |
Hgene | PDE4D | chr5:59284315 | chr17:26449629 | ENST00000405755 | - | 1 | 15 | 386_715 | 0 | 688.0 | Domain | PDEase |
Hgene | PDE4D | chr5:59284315 | chr17:26449629 | ENST00000502484 | - | 3 | 17 | 386_715 | 90.66666666666667 | 749.0 | Domain | PDEase |
Hgene | PDE4D | chr5:59284315 | chr17:26449629 | ENST00000502575 | - | 1 | 6 | 386_715 | 0 | 220.0 | Domain | PDEase |
Hgene | PDE4D | chr5:59284315 | chr17:26449629 | ENST00000503258 | - | 1 | 15 | 386_715 | 0 | 680.0 | Domain | PDEase |
Hgene | PDE4D | chr5:59284315 | chr17:26449629 | ENST00000507116 | - | 1 | 15 | 386_715 | 0 | 746.0 | Domain | PDEase |
Hgene | PDE4D | chr5:59284315 | chr17:26449629 | ENST00000546160 | - | 2 | 16 | 386_715 | 90.66666666666667 | 749.0 | Domain | PDEase |
Hgene | PDE4D | chr5:59284315 | chr17:26449629 | ENST00000317118 | - | 1 | 10 | 462_466 | 0 | 519.0 | Nucleotide binding | cAMP |
Hgene | PDE4D | chr5:59284315 | chr17:26449629 | ENST00000340635 | - | 1 | 15 | 462_466 | 0 | 810.0 | Nucleotide binding | cAMP |
Hgene | PDE4D | chr5:59284315 | chr17:26449629 | ENST00000358923 | - | 1 | 11 | 462_466 | 0 | 508.0 | Nucleotide binding | cAMP |
Hgene | PDE4D | chr5:59284315 | chr17:26449629 | ENST00000360047 | - | 1 | 15 | 462_466 | 0 | 674.0 | Nucleotide binding | cAMP |
Hgene | PDE4D | chr5:59284315 | chr17:26449629 | ENST00000405755 | - | 1 | 15 | 462_466 | 0 | 688.0 | Nucleotide binding | cAMP |
Hgene | PDE4D | chr5:59284315 | chr17:26449629 | ENST00000502484 | - | 3 | 17 | 462_466 | 90.66666666666667 | 749.0 | Nucleotide binding | cAMP |
Hgene | PDE4D | chr5:59284315 | chr17:26449629 | ENST00000502575 | - | 1 | 6 | 462_466 | 0 | 220.0 | Nucleotide binding | cAMP |
Hgene | PDE4D | chr5:59284315 | chr17:26449629 | ENST00000503258 | - | 1 | 15 | 462_466 | 0 | 680.0 | Nucleotide binding | cAMP |
Hgene | PDE4D | chr5:59284315 | chr17:26449629 | ENST00000507116 | - | 1 | 15 | 462_466 | 0 | 746.0 | Nucleotide binding | cAMP |
Hgene | PDE4D | chr5:59284315 | chr17:26449629 | ENST00000546160 | - | 2 | 16 | 462_466 | 90.66666666666667 | 749.0 | Nucleotide binding | cAMP |
Tgene | NLK | chr5:59284315 | chr17:26449629 | ENST00000407008 | 0 | 11 | 106_111 | 152.66666666666666 | 528.0 | Compositional bias | Note=Poly-Ala | |
Tgene | NLK | chr5:59284315 | chr17:26449629 | ENST00000407008 | 0 | 11 | 115_119 | 152.66666666666666 | 528.0 | Compositional bias | Note=Poly-Ala | |
Tgene | NLK | chr5:59284315 | chr17:26449629 | ENST00000407008 | 0 | 11 | 22_25 | 152.66666666666666 | 528.0 | Compositional bias | Note=Poly-Ala | |
Tgene | NLK | chr5:59284315 | chr17:26449629 | ENST00000407008 | 0 | 11 | 27_34 | 152.66666666666666 | 528.0 | Compositional bias | Note=Poly-His | |
Tgene | NLK | chr5:59284315 | chr17:26449629 | ENST00000407008 | 0 | 11 | 42_48 | 152.66666666666666 | 528.0 | Compositional bias | Note=Poly-His | |
Tgene | NLK | chr5:59284315 | chr17:26449629 | ENST00000407008 | 0 | 11 | 71_83 | 152.66666666666666 | 528.0 | Compositional bias | Note=Poly-Ala | |
Tgene | NLK | chr5:59284315 | chr17:26449629 | ENST00000407008 | 0 | 11 | 138_427 | 152.66666666666666 | 528.0 | Domain | Protein kinase | |
Tgene | NLK | chr5:59284315 | chr17:26449629 | ENST00000407008 | 0 | 11 | 144_152 | 152.66666666666666 | 528.0 | Nucleotide binding | ATP |
Top |
Fusion Gene Sequence for PDE4D-NLK |
For in-frame fusion transcripts, we provide the fusion transcript sequences and fusion amino acid sequences. To have fusion amino acid sequence, we ran ORFfinder and chose the longest ORF among the all predicted ones. |
>In-frame_ENST00000546160_ENST00000407008_TCGA-G9-6499_PDE4D_chr5_59284315_-_NLK_chr17_26449629_length(transcript)=3143nt_BP=272nt ATGAAAAGAAATACCTGTGATTTGCTTTCTCGGAGCAAAAGTGCCTCTGAGGAAACACTACATTCCAGTAATGAAGAGGAAGACCCTTTC CGCGGAATGGAACCCTATCTTGTCCGGAGACTTTCATGTCGCAATATTCAGCTTCCCCCTCTCGCCTTCAGACAGTTGGAACAAGCTGAC TTGAAAAGTGAATCAGAGAACATTCAACGACCAACCAGCCTCCCCCTGAAGATTCTGCCGCTGATTGCTATCACTTCTGCAGAATCCAGT GGGTCAGTAACAGATCCAAGAGATGGAAAGAGAGTAGCGCTCAAAAAGATGCCCAACGTCTTCCAGAATCTGGTCTCTTGCAAAAGGGTC TTCCGGGAATTGAAGATGTTGTGTTTTTTTAAGCATGATAATGTACTCTCTGCCCTTGACATACTCCAACCTCCACACATTGACTATTTT GAAGAAATATATGTTGTCACAGAATTGATGCAGAGTGACCTACATAAAATTATCGTCTCTCCTCAACCACTCAGCTCAGATCATGTCAAA GTTTTTCTTTATCAGATTTTGCGAGGTTTGAAATATCTCCATTCAGCTGGCATTTTACATCGAGACATTAAGCCAGGGAATCTCCTTGTG AACAGCAACTGTGTTCTAAAGATTTGTGATTTTGGATTGGCCAGAGTGGAAGAATTAGATGAATCCCGTCATATGACTCAGGAAGTTGTT ACTCAGTATTATCGGGCTCCAGAAATCCTGATGGGCAGCCGTCATTACAGCAATGCTATTGACATCTGGTCTGTGGGATGTATCTTTGCA GAACTACTAGGACGAAGAATATTGTTTCAGGCACAGAGTCCCATTCAGCAGTTGGATTTGATCACGGATCTGTTGGGCACACCATCACTG GAAGCAATGAGGACAGCTTGTGAAGGCGCTAAGGCACATATACTCAGGGGTCCTCATAAACAGCCATCTCTTCCTGTACTCTATACCCTG TCTAGCCAGGCTACACATGAAGCTGTTCATCTCCTTTGCAGGATGTTGGTCTTTGATCCATCCAAAAGAATATCCGCTAAGGATGCCTTA GCCCACCCCTACCTAGATGAAGGGCGACTACGATATCACACATGTATGTGTAAATGTTGCTTTTCCACCTCCACTGGAAGAGTTTATACC AGTGACTTTGAGCCTGTCACCAATCCCAAATTTGATGACACTTTCGAGAAGAACCTCAGTTCTGTCCGACAGGTTAAAGAAATTATTCAT CAGTTCATTTTGGAACAGCAGAAAGGAAACAGAGTGCCTCTCTGCATCAACCCTCAGTCTGCTGCTTTTAAGAGCTTTATTAGTTCCACT GTTGCTCAGCCATCTGAGATGCCCCCATCTCCTCTGGTGTGGGAGTGATGGTGGAAGATAATGTACTACTGAAGATGTAATGTAGCTTTC CACTGGAGTCTGGGATTTGCAATTCTGGAGGTTAATCATGCTTGTACTGTAATTTTACTAATGAAGTTTTAAATTAACAACCACTACTTG TATGATATGAATAATATTTAGAAATGTTACTAGACTTTTAATCTTGTAAAGTGGTTGTGCTTTTAGAAGAAAAATATTTTACCCAGAGTT GCACATGTTTTATGAATTTAGTGCAGCTGTTATGGCTCACCTCAGAACAAAAGAGAATTGAACCAAATTTGGGAGTTTGGGGTTTTATGT TTTGTTTTTCTTTTCTAAAATGAAGTGAGATTGTTCACACACACACACACACACACACACACACACAAACACAAAGGACAGTCATACATT TTGATATTTGAGCCATTCCTAAAGATTTGGGGTTTTCTAAAACTAAAGAATCTAGGAACCTTGCCTGCGACCAATCATGGAGCCACGTGA GCTGATCGTGGCTGCACCTGGGGGGAGGGTAGGGAGGAGGGGCATGCCACCTAATGATCAAGCCCTATAATTAGCTTCTCATTAGAGCCG TGATGGTGATGTGTGCTGTCTAAAATCCAATGTTGTGGGTAGAGAGAATGAGTTTGTGACTAGGAGAGACTAAACTTTTGTTTTCCTTAC CCAGTATAAATATATATATATATATTTAATCTATTTTTATTAGAAGTTTTTCTGCTCTTTCTTACATAAAAGAACCCCAAGCATGCATCT TTCATGTGTGTAAATAATTCATTTCTGGGCTAATTTCAAAAGAATCCCAATATTGCTGTATAGAAAGAGAACTAGCTTGCACATTTTAGG TCTGTGAAATTTTGTGAGACTTTTCCTGCACTGGACAGTAAAAAAATAATAAAAGACAAAAACAAATTTAAAAAAAAATTTAAGCCACAA AAAAAGGCACATAGGGAATTATGTCAAATGTGTTTGTGTCCTTAGGCAAAGCTGTGGGAGTCTTGAAATGTCACAGTAGTAAATAACTTA TTACTTTTTGACAAGTTCTTTTTTTCTGTTGGAACACTGAATTCTTCTGTGCATATGTACATATGAATACAAATCGAAGGCCTCTACCTC CTGGAGTTATACAACTTGGCTTGTTTACCTCCACATGCTGATGATGACTATTTTTTTTTTTTGAGTTCAGTGTGGAGACTTGAAACTTGA ATGTCCCTTCCAACTTTTATATTAAAAATAAAAAGACAAGAAAATTGAAGATCATTTTTCACCTGTACAAGGAATACTAATGGATCGTCT TAAAATTGGTCTAGGAAAAAACCTTGGTGTGTGTTATGGACAATTAACTGTTAAAGTTATTGTAAGTTATCTGTATTTAGCAGAGTATTT TCAACTTGAGTGATCTGAGCTGAATTTGAAGACTATTAATAAGTTATGTTTGGAAGTTTTAACTTCAATGAAGTAATTATTTGCTGTGAA AGAAACAAACATTGAATTACTAAACAAAGATGGTGCAATATCTTTGTTTTTTTTTTATGAGGCTCCTGAGAATCAACCCAACTGAAGCAT TTCAATTCACTTGAATGAGAAACGTGTTTAGTATCAAAAGAGCCCAAGAAGACACTGGTGTGAAAGGTACAATCTCAGAGGTTGGTCAAT >In-frame_ENST00000546160_ENST00000407008_TCGA-G9-6499_PDE4D_chr5_59284315_-_NLK_chr17_26449629_length(amino acids)=465AA_start in transcript=0_stop in transcript=1397 MKRNTCDLLSRSKSASEETLHSSNEEEDPFRGMEPYLVRRLSCRNIQLPPLAFRQLEQADLKSESENIQRPTSLPLKILPLIAITSAESS GSVTDPRDGKRVALKKMPNVFQNLVSCKRVFRELKMLCFFKHDNVLSALDILQPPHIDYFEEIYVVTELMQSDLHKIIVSPQPLSSDHVK VFLYQILRGLKYLHSAGILHRDIKPGNLLVNSNCVLKICDFGLARVEELDESRHMTQEVVTQYYRAPEILMGSRHYSNAIDIWSVGCIFA ELLGRRILFQAQSPIQQLDLITDLLGTPSLEAMRTACEGAKAHILRGPHKQPSLPVLYTLSSQATHEAVHLLCRMLVFDPSKRISAKDAL AHPYLDEGRLRYHTCMCKCCFSTSTGRVYTSDFEPVTNPKFDDTFEKNLSSVRQVKEIIHQFILEQQKGNRVPLCINPQSAAFKSFISST -------------------------------------------------------------- |
Top |
Fusion Gene PPI Analysis for PDE4D-NLK |
Go to ChiPPI (Chimeric Protein-Protein interactions) to see the chimeric PPI interaction in |
Protein-protein interactors with each fusion partner protein in wild-type (BIOGRID-3.4.160) |
Hgene | Hgene's interactors | Tgene | Tgene's interactors |
- Retained PPIs in in-frame fusion. |
Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Still interaction with |
- Lost PPIs in in-frame fusion. |
Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Interaction lost with |
- Retained PPIs, but lost function due to frame-shift fusion. |
Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Interaction lost with |
Top |
Related Drugs for PDE4D-NLK |
Drugs targeting genes involved in this fusion gene. (DrugBank Version 5.1.8 2021-05-08) |
Partner | Gene | UniProtAcc | DrugBank ID | Drug name | Drug activity | Drug type | Drug status |
Top |
Related Diseases for PDE4D-NLK |
Diseases associated with fusion partners. (DisGeNet 4.0) |
Partner | Gene | Disease ID | Disease name | # pubmeds | Source |
Hgene | PDE4D | C3553250 | ACRODYSOSTOSIS 2 WITH OR WITHOUT HORMONE RESISTANCE | 4 | CTD_human;GENOMICS_ENGLAND;UNIPROT |
Hgene | PDE4D | C0011581 | Depressive disorder | 3 | PSYGENET |
Hgene | PDE4D | C0004096 | Asthma | 2 | CTD_human |
Hgene | PDE4D | C0011570 | Mental Depression | 2 | PSYGENET |
Hgene | PDE4D | C0033578 | Prostatic Neoplasms | 2 | CTD_human |
Hgene | PDE4D | C0220659 | Acrodysostosis | 2 | CTD_human;GENOMICS_ENGLAND;ORPHANET |
Hgene | PDE4D | C0376358 | Malignant neoplasm of prostate | 2 | CTD_human |
Hgene | PDE4D | C0036341 | Schizophrenia | 1 | PSYGENET |
Hgene | PDE4D | C0236733 | Amphetamine-Related Disorders | 1 | CTD_human |
Hgene | PDE4D | C0236804 | Amphetamine Addiction | 1 | CTD_human |
Hgene | PDE4D | C0236807 | Amphetamine Abuse | 1 | CTD_human |
Hgene | PDE4D | C3276228 | ACRODYSOSTOSIS 1 WITH OR WITHOUT HORMONE RESISTANCE | 1 | CTD_human;GENOMICS_ENGLAND |